Ppt sd metabolico
•0 recomendaciones•767 vistas
Denunciar
Compartir
Descargar para leer sin conexión
Más contenido relacionado
La actualidad más candente
La actualidad más candente(19)
Destacado
Destacado(9)
Similar a Ppt sd metabolico
Similar a Ppt sd metabolico(20)
Más de wilderzuniga
Más de wilderzuniga(20)
Ppt sd metabolico
- 1. SSíínnddrroommee mmeettaabbóólliiccoo PPrreevveenncciióónn ddee eennffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr DDrr.. JJoosséé AAmmaayyaa HHoossppiittaall NNaacciioonnaall HHiippóólliittoo UUnnaannuuee CCllíínniiccaa IInntteerrnnaacciioonnaall
- 2. Tres o más ddee llooss ssiigguuiieenntteess:: • OObbeessiiddaadd aabbddoommiinnaall • CCiinnttuurraa >> 110022 ccmm eenn hhoommbbrreess • CCiinnttuurraa >> 8888 ccmm eenn mmuujjeerreess • GGlluucceemmiiaa ppllaassmmááttiiccaa eenn aayyuunnaass >> 111100 mmgg//ddll • TTeennssiióónn aarrtteerriiaall >> 113300 // 8855 mmmmHHgg • TTrriigglliiccéérriiddooss >> 115500 mmgg//ddll • HHDDLL--ccoolleesstteerrooll • << 4400 mmgg//ddll eenn hhoommbbrreess • << 5500 mmgg//ddll eenn mmuujjeerreess 2 DDeeffiinniicciióónn OOMMSS ((11999999)) RReessiisstteenncciiaa aa llaa iinnssuulliinnaa ((<<ccuuaarrttiill iinnffeerriioorr ddee llaa ppoobbllaacciióónn ccoonnttrrooll)),, yy//oo GGlluucceemmiiaa ppllaassmmááttiiccaa eenn aayyuunnaass >> 111100 mmgg//ddll yy//oo gglluuccèèmmiiaa aa lleess 22hh ddee uunnaa SSOOGG >> 114400 mmgg//ddll CCoonn 22 óó mmááss ddee llooss ssiigguuiieenntteess:: TTAASS >> 114400 yy//oo TTAADD >> 900 mmmmHHgg TTrriigglliiccéérriiddooss >> 115500 mmgg//ddll yy//oo HHDDLL--ccoolleesstteerrooll << 3355 mmgg//ddll eenn hhoommbbrreess oo << 339 mmgg//ddll eenn mmuujjeerreess.. WWHHRR>>00..9 HH oo 00..8855 MM yy//oo IIMMCC >> 3300 kkgg//mm22 MMiiccrrooaallbbuummiinnuurriiaa..EEUUAA>>2200mgg//mmii nn oo ccoocciieennttee aallbb//ccrreeaa >> 2200 mmgg//gg NNCCEEPP ((22000011))
- 3. 3 DDeeffiinniicciióónn IIDDFF ((22000055)) • OObbeessiiddaadd aabbddoommiinnaall** • CCiinnttuurraa >> 944 ccmm eenn hhoommbbrreess • CCiinnttuurraa >> 8800 ccmm eenn mmuujjeerreess MMááss 22 ddee llooss ssiigguuiieenntteess:: • GGlluucceemmiiaa ppllaassmmááttiiccaa eenn aayyuunnaass >> 110000 mmgg//ddll oo ttttoo • TTeennssiióónn aarrtteerriiaall >> 113300//8855 mmmmHHgg oo ttttoo • TTrriigglliiccéérriiddooss >> 115500 mmgg//ddll oo ttttoo • HHDDLL--ccoolleesstteerrooll oo ttttoo • << 4400 mmgg//ddll eenn hhoommbbrreess • << 5500 mmgg//ddll eenn mmuujjeerreess ** vvaarriiaabbllee sseeggúúnn eettnniiaa NNCCEEPP ((22000055)) TTrreess oo mmááss ddee llooss ssiigguuiieenntteess:: • OObbeessiiddaadd aabbddoommiinnaall • CCiinnttuurraa >> 110022 ccmm eenn hhoommbbrreess • CCiinnttuurraa >> 8888 ccmm eenn mmuujjeerreess • GGlluucceemmiiaa ppllaassmmááttiiccaa eenn aayyuunnaass >> 110000 mmgg//ddll oo ttttoo • TTeennssiióónn aarrtteerriiaall >> 113300//8855 mmmmHHgg oo ttttoo • TTrriigglliiccéérriiddooss >> 115500 mmgg//ddll oo ttttoo** • HHDDLL--ccoolleesstteerrooll • << 4400 mmgg//ddll eenn hhoommbbrreess • << 5500 mmgg//ddll eenn mmuujjeerreess ** FFiibbrraattoo oo AAcc nniiccoottíínniiccoo
- 4. SSíínnddrroommee mmeettaabbóólliiccoo CCoonncceeppttoo SSíínnddrroommee mmeettaabbóólliiccoo MMeejjoorrííaa ssiinnccrróónniiccaa FFRRCCVV ccoonn ccaammbbiiooss eenn eessttiilloo ddee vviiddaa GGlluucceemmiiaa eelleevvaaddaa LLDDLL--CC eelleevvaaddoo OObbeessiiddaadd cceennttrraall HHDDLL--CC bbaajjoo TTrriigglliicc.. eelleevvaaddooss TTAASS eelleevvaaddaa EEnnffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr EEddaadd TTaabbaaccoo SSeexxoo MM HHª ffaamm ++
- 5. LLaa pprreevvaalleenncciiaa ddee SSMM sseeggúúnn 100 90 80 70 60 50 40 30 20 10 0 ccrriitteerriiooss uuttiilliizzaaddooss 40-49 50-59 60-69 40-49 50-59 60-69 Prevalencia (% población) ATPIII IDF Edad (años) Varones Mujeres Adams S. Diabetes Care 2005 EEssttaaddooss UUnniiddooss
- 6. SSíínnddrroommee mmeettaabbóólliiccoo EEll pprroobblleemmaa LLDDLL--CC eelleevvaaddoo SSíínnddrroommee mmeettaabbóólliiccoo OOllvviiddaa oottrrooss mmaarrccaaddoorreess ddee aaccuueerrddoo ccoonn bbaassee ffiissiiooppaattoollóóggiiccaa SSuu vvaalloorr ccoommoo ddiiaaggnnóóssttiiccoo ssoobbrreeppaassaa aall ccoonncceeppttoo EEnnffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr EEddaadd TTaabbaaccoo SSeexxoo MM HHª ffaamm ++
- 7. TThhee MMeettaabb.. SSyynnddrroommee:: RRiiqquueessccaatt iinn PPaaccee RReeaavveenn,, CClliinn CChheemmiissttrryy 22000055 Circulation, 25 octubre 2005 EEnn ccoonnttrraa:: Diabetes Care, septiembre 2005 AA ffaavvoorr:: TThhee MMeettaabboolliicc SSyynnddrroommee SSttiillll LLiivveess GGrruunnddyy,, CClliinn CChheemmiissttrryy 22000055
- 8. SSíínnddrroommee mmeettaabbóólliiccoo RReellaacciióónn ccoonn eennffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr SSíínnddrroommee mmeettaabbóólliiccoo PPrreevveenncciióónn 11aarriiaa EEnn aauusseenncciiaa DDMM 22 EEnn pprreesseenncciiaa DDMM 22 EEnnffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr PPrreevveenncciióónn 22aarriiaa
- 9. SSíínnddrroommee mmeettaabbóólliiccoo RReellaacciióónn ccoonn eennffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr SSíínnddrroommee mmeettaabbóólliiccoo PPrreevveenncciióónn 11aarriiaa Ö EEnn aauusseenncciiaa DDMM 22 EEnn pprreesseenncciiaa DDMM 22 EEnnffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr PPrreevveenncciióónn 22aarriiaa Ö
- 10. SSíínnddrroommee mmeettaabbóólliiccoo RReellaacciióónn ccoonn eennffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr SSíínnddrroommee mmeettaabbóólliiccoo PPrreevveenncciióónn 11aarriiaa Ö EEnn aauusseenncciiaa DDMM 22 EEnn pprreesseenncciiaa DDMM 22 EEnnffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr PPrreevveenncciióónn 22aarriiaa Ö DDMM >>SSMM Riesgo relativo Prevención 1aria EEssttuuddiioo HHOOOORRNN DDeekkkkeerr JJMM,, CCiirrccuullaattiioonn 22000055
- 11. SSíínnddrroommee mmeettaabbóólliiccoo RReellaacciióónn ccoonn eennffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr SSíínnddrroommee mmeettaabbóólliiccoo PPrreevveenncciióónn 11aarriiaa Ö EEnn aauusseenncciiaa DDMM 22 EEnn pprreesseenncciiaa DDMM 22 Prevención 2aria no DM/noSM DDMM >>SSMM EEnnffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr PPrreevveenncciióónn 22aarriiaa Ö DM SM DDMM >>SSMM
- 12. SSíínnddrroommee mmeettaabbóólliiccoo RReellaacciióónn ccoonn eennffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr SSíínnddrroommee mmeettaabbóólliiccoo PPrreevveenncciióónn 11aarriiaa OOllvviiddaa oottrrooss mmaarrccaaddoorreess ddee aaccuueerrddoo ccoonn bbaassee ffiissiiooppaattoollóóggiiccaa Ö EEnn aauusseenncciiaa DDMM 22 EEnn pprreesseenncciiaa DDMM 22 PPrrootteeíínnaa CC rreeaaccttiivvaa EEnnffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr PPrreevveenncciióónn 22aarriiaa Ö SSuu vvaalloorr ccoommoo ddiiaaggnnóóssttiiccoo ssoobbrreeppaassaa aall ccoonncceeppttoo ¿MMeejjoorr pprreeddiicccciióónn EECCVV qquuee ccoonn eeccuuaacciióónn FFrraammiinngghhaamm?? PPrroobblleemmaass
- 13. ¿MMeejjoorr pprreeddiicccciióónn EECCVV qquuee ccoonn SSaann AAnnttoonniioo HHeeaarrtt SSttuuddyy,, nn== 22557700,, ffoollllooww uupp 77..55 yy FFrraammiinngghhaamm ffiijjaaddoo aa 3344,,22%% FFrraammiinngghhaamm ffiijjaaddoo aa 6677,,33%% 2200,,00%% Stern MMPP,, DDiiaabbeetteess CCaarree 22000044 SSeennssiibbiilliiddaadd FFaallssooss ppoossiittiivvooss SSdd.. MMeettaabbóólliiccoo SSdd MMeettaabbóólliiccoo OObbeessiiddaadd TTeennssiióónn aarrtteerriiaall TTrriigglliiccéérriiddooss CCoolleesstteerrooll HHDDLL GGlluucceemmiiaa eenn aayyuunnaass 6677,,33%% 3344,,22%% EEccuuaa.. FFrraammiinngghhaamm EEddaadd GGéénneerroo CCoolleesstteerrooll ttoottaall TTaabbaaqquuiissmmoo CCoolleesstteerrooll HHDDLL TTeennssiióónn aarrtteerriiaall ssiissttóólliiccaa DDiiaabbeetteess ((00--11)) 8811,,44%% DDiiccoottóómmiiccoo Ponderado eeccuuaacciióónn FFrraammiinngghhaamm??
- 14. TTrraattaammiieennttoo FFeennoottííppiiccoo OObbeessiiddaadd cceennttrraall ((cciirrccuummffeerreenncciiaa cciinnttuurraa eelleevvaaddoo)) DDiissttrriibbuucciióónn ggrraassaa ccoorrppoorraall GG.. vviisscceerraall GG.. ssuubbccuuttáánneeaa MMoolleeccuullaarr RReessiisstteenncciiaa aa iinnssuulliinnaa IInnffllaammaacciióónn Ö NNoo ttttoo sseelleeccttiivvoo NNoo hhooyy ppoorr hhooyy NNoo hhooyy ppoorr hhooyy
- 15. TTrraattaammiieennttoo SSdd.. MMeettaabbóólliiccoo SSíínnddrroommee mmeettaabbóólliiccoo MMeejjoorrííaa ssiinnccrróónniiccaa FFRRCCVV ccoonn ccaammbbiiooss eenn eessttiilloo ddee vviiddaa OObbeessiiddaadd cceennttrraall 55--1100%% ppeessoo ccoorrppoorraall GGlluucceemmiiaa eelleevvaaddaa LLDDLL--CC eelleevvaaddoo HHDDLL--CC bbaajjoo TTrriigglliicc.. eelleevvaaddooss TTAASS eelleevvaaddaa EEnnffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr EEddaadd TTaabbaaccoo SSeexxoo MM HHª ffaamm ++
- 16. FFààrrmmaaccooss ttrraattaammiieennttoo oobbeessiiddaadd SSeeññaalleess ppeerriifféérriiccaass LLeeppttiinnaa IInnssuulliinnaa SSiibbuuttrraammiinnaa ((EExxcc)) IInnggeessttaa GGaassttoo eenneerrggééttiiccoo OOrrlliissttaatt BBaallaannccee EEnneerrggééttiiccoo SSeeññaalleess cceennttrraalleess RRiimmoonnaabbaanntt (( EExxcc))
- 17. TTrraattaammiieennttoo SSdd.. MMeettaabbóólliiccoo SSíínnddrroommee mmeettaabbóólliiccoo OObbeessiiddaadd 55--1100%% ppeessoo ccoorrppoorraall GGlluucceemmiiaa eelleevvaaddaa LLDDLL--CC eelleevvaaddoo HHDDLL--CC bbaajjoo TTrriigglliicc.. eelleevvaaddooss TTAASS eelleevvaaddaa EEnnffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr EEddaadd TTaabbaaccoo SSeexxoo MM HHª ffaamm ++ ??
- 18. TTrraattaammiieennttoo SSdd.. MMeettaabbóólliiccoo LLooss pprroobblleemmaass LLDDLL--CC eelleevvaaddoo SSíínnddrroommee mmeettaabbóólliiccoo PPuuddiieerraa oobbvviiaarrssee ccaammbbiioo EEVV eenn qquuiieenn ttaammbbiiéénn pprreecciissaa PPuueeddee lllleevvaarr aa nnoo ttrraattaarr aaddeeccuuaaddaammeennttee FFRRCCVV mmuuyy iimmppoorrttaanntteess ¿LLooss ccaammbbiiooss eenn EEVV nnoo eerraann yyaa ppaarrttee ddeell ttrraattaammiieennttoo ddee FFRRCCVV?? EEnnffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr EEddaadd TTaabbaaccoo SSeexxoo MM HHª ffaamm ++
- 19. RReeccoommeennddaacciioonneess SSíínnddrroommee mmeettaabbóólliiccoo CCaallccuullaarr rriieessggoo eeccuuaacciióónn FFrraammiinngghhaamm BBaajjoo rriieessggoo ((<<1100%% aa 1100 aa)) RRiieessggoo MMeeddiioo ((1100 aa 2200%%)) AAllttoo rriieessggoo ((>>2200%% aa 1100 aa)) OObbjjeettiivvooss ddee ttttoo sseeggúúnn rriieessggoo ccaallccuullaaddoo TTAASS//TTAADD >>113300//8855 TTgg>>115500 HHDDLL<<4400 HHTTAA TTaabbaaccoo GGlluucc >>110000 DDiiaabbeetteess ttiippoo 22 LLDDLL--CC eelleevvaaddoo CCaammbbiiooss eessttiilloo ddee vviiddaa The metabolic syndrome: Modify root causes, Treat risk factors
- 20. TTrraattaammiieennttoo FFeennoottííppiiccoo Ö hhooyy ppoorr hhooyy OObbeessiiddaadd cceennttrraall ((cciirrccuummffeerreenncciiaa cciinnttuurraa eelleevvaaddoo)) DDiissttrriibbuucciióónn ggrraassaa ccoorrppoorraall GG.. vviisscceerraall GG.. ssuubbccuuttáánneeaa MMoolleeccuullaarr NNoo RReessiisstteenncciiaa aa iinnssuulliinnaa IInnffllaammaacciióónn NNoo ttttoo sseelleeccttiivvoo NNoo hhooyy ppoorr hhooyy
- 21. TTrraattaammiieennttoo FFeennoottííppiiccoo Ö OObbeessiiddaadd cceennttrraall ((cciirrccuummffeerreenncciiaa cciinnttuurraa eelleevvaaddoo))
- 22. TTrraattaammiieennttoo FFeennoottííppiiccoo Ö OObbeessiiddaadd cceennttrraall ((cciirrccuummffeerreenncciiaa cciinnttuurraa eelleevvaaddoo)) GGlluucc >>110000 DDiiaabbeetteess ttiippoo 22 TTAASS//TTAADD >>113300//8855 HHTTAA TTgg>>115500 HHDDLL<<4400 Ö Ö Ö ++ oottrrooss FFRRCCVV
- 23. TTrraattaammiieennttoo SSdd.. MMeettaabbóólliiccoo LLooss pprroobblleemmaass LLDDLL--CC eelleevvaaddoo SSíínnddrroommee mmeettaabbóólliiccoo PPuuddiieerraa oobbvviiaarrssee ccaammbbiioo EEVV eenn qquuiieenn ttaammbbiiéénn pprreecciissaa PPuueeddee lllleevvaarr aa nnoo ttrraattaarr aaddeeccuuaaddaammeennttee FFRRCCVV mmuuyy iimmppoorrttaanntteess ¿LLooss ccaammbbiiooss eenn EEVV nnoo eerraann yyaa ppaarrttee ddeell ttrraattaammiieennttoo ddee FFRRCCVV?? Parecería que hay margen para mejorar la EEnnffeerrmmeeddaadd ccaarrddiioovvaassccuullaarr tasa de recomendaciones sobre cambios en EV EEddaadd TTaabbaaccoo SSeexxoo MM HHª ffaamm ++
- 24. RReessuummeenn • EEll ccoonncceeppttoo ddee SSdd.. MMeettaabbóólliiccoo eess úúttiill ppaarraa llaa iiddeennttiiffiiccaacciióónn ddee ppaacciieenntteess ccoonn rriieessggoo CCVV yy ppaarraa ssuubbrraayyaarr llaa iimmppoorrttaanncciiaa ddeell eessttiilloo ddee vviiddaa ((eessppeecciiaallmmeennttee eenn rreellaacciióónn ccoonn llaa oobbeessiiddaadd cceennttrraall)) eenn llaa pprreevveenncciióónn yy ttrraattaammiieennttoo ddee llaa EECCVV
- 25. RReessuummeenn • AA ppeessaarr ddee eelllloo nnoo ddeebbee ssoobbrreevvaalloorraarrssee eell ddiiaaggnnóóssttiiccoo:: • EEss nneecceessaarriiaa uunnaa mmeejjoorr ddeeffiinniicciióónn ddeell SSMM • EEqquuiilliibbrraannddoo ffaacciilliiddaadd eenn eell ddiiaaggnnóóssttiiccoo ccoonn uuttiilliiddaadd ccllíínniiccaa • NNoo ddeebbee ccoonnssiiddeerraarrssee uunn eeqquuiivvaalleennttee ddee EECCVV nnii ssuussttiittuuiirr aa oottrraass eessccaallaass ddee eessttiimmaacciióónn ddee RRCCVV • NNoo ddeebbee hhaacceerrnnooss oollvviiddaarr ddee qquuee eell ttrraattaammiieennttoo ffaarrmmaaccoollóóggiiccoo ddee llooss FFRRCCVV eessttaabblleecciiddooss eess uunnaa pprriioorriiddaadd..
- 26. Gracias
Notas del editor
- Metabolic syndrome increases risk for CHD and type 2 diabetes The National Cholesterol Education Program (NCEP) has traditionally focused on high low-density lipoprotein cholesterol (LDL-C) as a risk factor for coronary heart disease (CHD). In the NCEP Adult Treatment Panel III (ATP III) recommendations published in JAMA in 2001, the NCEP suggested that the metabolic syndrome might independently predict the development of both type 2 diabetes and CHD. Note that in most definitions of the metabolic syndrome whether NCEP, WHO or AACE, diabetic subjects are included among those subjects who now have the metabolic syndrome. Most papers examining the relationship of the metabolic syndrome to cardiovascular disease have excluded diabetic subjects with the metabolic syndrome since diabetic subjects are at high risk of cardiovascular disease whether they have the metabolic syndrome or not. Note also that the arrow pointing from the metabolic syndrome to type 2 diabetes refers to non-diabetic metabolic syndrome patients. References: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
- Rexrode KM, Carey VJ, Hennekens CH et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998;280:1843-8.
- Metabolic syndrome increases risk for CHD and type 2 diabetes The National Cholesterol Education Program (NCEP) has traditionally focused on high low-density lipoprotein cholesterol (LDL-C) as a risk factor for coronary heart disease (CHD). In the NCEP Adult Treatment Panel III (ATP III) recommendations published in JAMA in 2001, the NCEP suggested that the metabolic syndrome might independently predict the development of both type 2 diabetes and CHD. Note that in most definitions of the metabolic syndrome whether NCEP, WHO or AACE, diabetic subjects are included among those subjects who now have the metabolic syndrome. Most papers examining the relationship of the metabolic syndrome to cardiovascular disease have excluded diabetic subjects with the metabolic syndrome since diabetic subjects are at high risk of cardiovascular disease whether they have the metabolic syndrome or not. Note also that the arrow pointing from the metabolic syndrome to type 2 diabetes refers to non-diabetic metabolic syndrome patients. References: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
- Metabolic syndrome increases risk for CHD and type 2 diabetes The National Cholesterol Education Program (NCEP) has traditionally focused on high low-density lipoprotein cholesterol (LDL-C) as a risk factor for coronary heart disease (CHD). In the NCEP Adult Treatment Panel III (ATP III) recommendations published in JAMA in 2001, the NCEP suggested that the metabolic syndrome might independently predict the development of both type 2 diabetes and CHD. Note that in most definitions of the metabolic syndrome whether NCEP, WHO or AACE, diabetic subjects are included among those subjects who now have the metabolic syndrome. Most papers examining the relationship of the metabolic syndrome to cardiovascular disease have excluded diabetic subjects with the metabolic syndrome since diabetic subjects are at high risk of cardiovascular disease whether they have the metabolic syndrome or not. Note also that the arrow pointing from the metabolic syndrome to type 2 diabetes refers to non-diabetic metabolic syndrome patients. References: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
- Metabolic syndrome increases risk for CHD and type 2 diabetes The National Cholesterol Education Program (NCEP) has traditionally focused on high low-density lipoprotein cholesterol (LDL-C) as a risk factor for coronary heart disease (CHD). In the NCEP Adult Treatment Panel III (ATP III) recommendations published in JAMA in 2001, the NCEP suggested that the metabolic syndrome might independently predict the development of both type 2 diabetes and CHD. Note that in most definitions of the metabolic syndrome whether NCEP, WHO or AACE, diabetic subjects are included among those subjects who now have the metabolic syndrome. Most papers examining the relationship of the metabolic syndrome to cardiovascular disease have excluded diabetic subjects with the metabolic syndrome since diabetic subjects are at high risk of cardiovascular disease whether they have the metabolic syndrome or not. Note also that the arrow pointing from the metabolic syndrome to type 2 diabetes refers to non-diabetic metabolic syndrome patients. References: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
- Metabolic syndrome increases risk for CHD and type 2 diabetes The National Cholesterol Education Program (NCEP) has traditionally focused on high low-density lipoprotein cholesterol (LDL-C) as a risk factor for coronary heart disease (CHD). In the NCEP Adult Treatment Panel III (ATP III) recommendations published in JAMA in 2001, the NCEP suggested that the metabolic syndrome might independently predict the development of both type 2 diabetes and CHD. Note that in most definitions of the metabolic syndrome whether NCEP, WHO or AACE, diabetic subjects are included among those subjects who now have the metabolic syndrome. Most papers examining the relationship of the metabolic syndrome to cardiovascular disease have excluded diabetic subjects with the metabolic syndrome since diabetic subjects are at high risk of cardiovascular disease whether they have the metabolic syndrome or not. Note also that the arrow pointing from the metabolic syndrome to type 2 diabetes refers to non-diabetic metabolic syndrome patients. References: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
- Metabolic syndrome increases risk for CHD and type 2 diabetes The National Cholesterol Education Program (NCEP) has traditionally focused on high low-density lipoprotein cholesterol (LDL-C) as a risk factor for coronary heart disease (CHD). In the NCEP Adult Treatment Panel III (ATP III) recommendations published in JAMA in 2001, the NCEP suggested that the metabolic syndrome might independently predict the development of both type 2 diabetes and CHD. Note that in most definitions of the metabolic syndrome whether NCEP, WHO or AACE, diabetic subjects are included among those subjects who now have the metabolic syndrome. Most papers examining the relationship of the metabolic syndrome to cardiovascular disease have excluded diabetic subjects with the metabolic syndrome since diabetic subjects are at high risk of cardiovascular disease whether they have the metabolic syndrome or not. Note also that the arrow pointing from the metabolic syndrome to type 2 diabetes refers to non-diabetic metabolic syndrome patients. References: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
- Metabolic syndrome increases risk for CHD and type 2 diabetes The National Cholesterol Education Program (NCEP) has traditionally focused on high low-density lipoprotein cholesterol (LDL-C) as a risk factor for coronary heart disease (CHD). In the NCEP Adult Treatment Panel III (ATP III) recommendations published in JAMA in 2001, the NCEP suggested that the metabolic syndrome might independently predict the development of both type 2 diabetes and CHD. Note that in most definitions of the metabolic syndrome whether NCEP, WHO or AACE, diabetic subjects are included among those subjects who now have the metabolic syndrome. Most papers examining the relationship of the metabolic syndrome to cardiovascular disease have excluded diabetic subjects with the metabolic syndrome since diabetic subjects are at high risk of cardiovascular disease whether they have the metabolic syndrome or not. Note also that the arrow pointing from the metabolic syndrome to type 2 diabetes refers to non-diabetic metabolic syndrome patients. References: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
- Metabolic syndrome increases risk for CHD and type 2 diabetes The National Cholesterol Education Program (NCEP) has traditionally focused on high low-density lipoprotein cholesterol (LDL-C) as a risk factor for coronary heart disease (CHD). In the NCEP Adult Treatment Panel III (ATP III) recommendations published in JAMA in 2001, the NCEP suggested that the metabolic syndrome might independently predict the development of both type 2 diabetes and CHD. Note that in most definitions of the metabolic syndrome whether NCEP, WHO or AACE, diabetic subjects are included among those subjects who now have the metabolic syndrome. Most papers examining the relationship of the metabolic syndrome to cardiovascular disease have excluded diabetic subjects with the metabolic syndrome since diabetic subjects are at high risk of cardiovascular disease whether they have the metabolic syndrome or not. Note also that the arrow pointing from the metabolic syndrome to type 2 diabetes refers to non-diabetic metabolic syndrome patients. References: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
- Metabolic syndrome increases risk for CHD and type 2 diabetes The National Cholesterol Education Program (NCEP) has traditionally focused on high low-density lipoprotein cholesterol (LDL-C) as a risk factor for coronary heart disease (CHD). In the NCEP Adult Treatment Panel III (ATP III) recommendations published in JAMA in 2001, the NCEP suggested that the metabolic syndrome might independently predict the development of both type 2 diabetes and CHD. Note that in most definitions of the metabolic syndrome whether NCEP, WHO or AACE, diabetic subjects are included among those subjects who now have the metabolic syndrome. Most papers examining the relationship of the metabolic syndrome to cardiovascular disease have excluded diabetic subjects with the metabolic syndrome since diabetic subjects are at high risk of cardiovascular disease whether they have the metabolic syndrome or not. Note also that the arrow pointing from the metabolic syndrome to type 2 diabetes refers to non-diabetic metabolic syndrome patients. References: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
- Metabolic syndrome increases risk for CHD and type 2 diabetes The National Cholesterol Education Program (NCEP) has traditionally focused on high low-density lipoprotein cholesterol (LDL-C) as a risk factor for coronary heart disease (CHD). In the NCEP Adult Treatment Panel III (ATP III) recommendations published in JAMA in 2001, the NCEP suggested that the metabolic syndrome might independently predict the development of both type 2 diabetes and CHD. Note that in most definitions of the metabolic syndrome whether NCEP, WHO or AACE, diabetic subjects are included among those subjects who now have the metabolic syndrome. Most papers examining the relationship of the metabolic syndrome to cardiovascular disease have excluded diabetic subjects with the metabolic syndrome since diabetic subjects are at high risk of cardiovascular disease whether they have the metabolic syndrome or not. Note also that the arrow pointing from the metabolic syndrome to type 2 diabetes refers to non-diabetic metabolic syndrome patients. References: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
- Metabolic syndrome increases risk for CHD and type 2 diabetes The National Cholesterol Education Program (NCEP) has traditionally focused on high low-density lipoprotein cholesterol (LDL-C) as a risk factor for coronary heart disease (CHD). In the NCEP Adult Treatment Panel III (ATP III) recommendations published in JAMA in 2001, the NCEP suggested that the metabolic syndrome might independently predict the development of both type 2 diabetes and CHD. Note that in most definitions of the metabolic syndrome whether NCEP, WHO or AACE, diabetic subjects are included among those subjects who now have the metabolic syndrome. Most papers examining the relationship of the metabolic syndrome to cardiovascular disease have excluded diabetic subjects with the metabolic syndrome since diabetic subjects are at high risk of cardiovascular disease whether they have the metabolic syndrome or not. Note also that the arrow pointing from the metabolic syndrome to type 2 diabetes refers to non-diabetic metabolic syndrome patients. References: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
- Metabolic syndrome increases risk for CHD and type 2 diabetes The National Cholesterol Education Program (NCEP) has traditionally focused on high low-density lipoprotein cholesterol (LDL-C) as a risk factor for coronary heart disease (CHD). In the NCEP Adult Treatment Panel III (ATP III) recommendations published in JAMA in 2001, the NCEP suggested that the metabolic syndrome might independently predict the development of both type 2 diabetes and CHD. Note that in most definitions of the metabolic syndrome whether NCEP, WHO or AACE, diabetic subjects are included among those subjects who now have the metabolic syndrome. Most papers examining the relationship of the metabolic syndrome to cardiovascular disease have excluded diabetic subjects with the metabolic syndrome since diabetic subjects are at high risk of cardiovascular disease whether they have the metabolic syndrome or not. Note also that the arrow pointing from the metabolic syndrome to type 2 diabetes refers to non-diabetic metabolic syndrome patients. References: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.